NXI Therapeutics

What NXI Therapeutics does

NXI Therapeutics AG (formerly NextImmune) is a privately held Swiss biotechnology company based in Basel that is developing a novel class of selective immunosuppressants for autoimmune diseases and organ transplantation. The company's scientific platform centers on modulators of the Coronin 1 signaling pathway, a protein that regulates T cell immune responses driving graft rejection and autoimmunity. Its lead candidate, IC1A, is designed to deplete or modulate Coronin 1 to achieve allo-selective immunosuppression — suppressing pathological T cell activity while preserving protective responses against infections, vaccination, and cancers. The underlying biology is derived from over 15 years of academic research conducted at the University of Basel by co-founder and CSO Dr. Rajesh Jayachandran, with mechanistic foundations traceable to the coronin biology work of board member Prof. Dr. Jean Pieters.

The business is pre-revenue and pre-clinical, with no commercial products or distribution channels. NXI's intended revenue model is dual-track: eventual drug sales following regulatory approval and, more proximately, licensing or partnership economics with larger pharmaceutical companies at development milestones — a strategy reflected in the binding development and supply agreement signed with India's Shilpa Medicare Limited in February 2026 covering a New Chemical Entity for autoimmune and alloimmune disorders. Customer base today is effectively zero end-users; the company serves healthcare providers and patients (horizontal segment) with autoimmune conditions and transplant recipients indirectly via future pharmaceutical partners. Headcount sits at 1–10 employees, total disclosed funding to date is CHF 3.5 million in extended pre-seed capital (plus modest non-dilutive grants), and NXI's near-term focus is IND-enabling work and a planned larger seed financing round.

Name

NXI Therapeutics

Legal name

NXI Therapeutics AG

Website

https://nxitherapeutics.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

NXI Therapeutics AG is a Basel-based, pre-revenue Swiss biotech developing Coronin 1 pathway modulators (lead candidate IC1A) as selective immunosuppressants for autoimmune diseases and organ transplantation, intending to commercialize via licensing and CDMO partnerships such as Shilpa Medicare.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Drug Development

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Immunosuppressive drugs
• Autoimmune disease therapy
• Organ transplant drugs
• Coronin 1 modulators
• Biopharmaceutical R&D

Headquarters

HQ city

Basel

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical Development and Licensing: Pre-revenue biotech company developing novel immunosuppressive drugs (IC1A candidate). Revenue will be generated through eventual drug sales following regulatory approval, and/or through licensing/partnership deals with larger pharmaceutical companies at various development milestones.

Go-to-market motion1 record

Marketing channels3 records

Core offering

NXI Therapeutics is a preclinical-stage biotechnology company developing a single novel therapeutic candidate, IC1A, which targets the Coronin 1 signaling pathway to induce allo- and auto-selective immunosuppression. The candidate is being advanced for autoimmune diseases and the prevention of organ transplant rejection, designed to suppress pathogenic T cell responses while preserving protective immunity against infections, vaccination, and cancers. The company intends to license or partner with larger pharmaceutical companies upon achieving clinical milestones.

Product overview

NXI Therapeutics is a privately held biotechnology company (AG) developing a single novel therapeutic candidate, IC1A, which is a Coronin 1 signaling pathway modulator. This drug is being developed as a next-generation selective immunosuppressant for autoimmune diseases and organ transplantation, with the objective of achieving high efficacy and safety without the adverse effects of conventional non-selective immunosuppressants like steroids, calcineurin blockers, and anti-metabolites. The company was previously known as NextImmune.

Differentiator

Problem solved

Functional benefit

Products and services

• IC1A

Quantifiable outcome

• Over 100 different autoimmune diseases and 5% of global population affected
• +3 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Four partnerships are on record, tiered core and minor.

• Shilpa Medicare LimitedcoreStrategic or Co-development Partner · 13 February 2026Shilpa Medicare Limited signed a binding development and supply agreement with NXI Therapeutics AG for a New Chemical Entity (NCE) targeting autoimmune and alloimmune disorders. The collaboration includes support for clinical development and GMP manufacturing. The deal aims to strengthen Shilpa's position in the biotech and CDMO sectors amidst its strategic shift towards innovation and global partnerships.
• University of BaselcoreOthersNXI Therapeutics has close ties with the University of Basel where co-founder Dr. Rajesh Jayachandran conducted over 15 years of coronin 1 research. The company maintains academic partnerships for research and development.
• Swiss Transplantation SocietyminorOthersThe Swiss Transplantation Society supports transplant research in Switzerland. NXI Therapeutics participates in Society activities and has received recognition through awards.
• BaseLaunchcoreOthersNXI Therapeutics was selected as one of the portfolio companies under the highly competitive BaseLaunch program in 2021, providing accelerator support and resources.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat3 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NXI Therapeutics